Specialized muscle cells possess the ability to divide in a way that promotes muscle repair and regeneration. Discovering key regulatory elements of this process and molecules to enhance it has been the core work of Satellos, a company pioneering novel small-molecule medicines for Duchenne muscle dystrophy and other muscle disorders. In this exclusive interview, Frank Gleeson, Cofounder and CEO of Satellos, explores further.
Click here to view a pdf of the article.
